Antibacterial Drugs Market by Routes of Administration (Enteral, Parenteral), Drug Class (Aminoglycoside, B – Lactams, Macrolides), Distribution Channel - Global Forecast 2024-2030
Description
Antibacterial Drugs Market by Routes of Administration (Enteral, Parenteral), Drug Class (Aminoglycoside, B – Lactams, Macrolides), Distribution Channel - Global Forecast 2024-2030
The Antibacterial Drugs Market size was estimated at USD 37.63 billion in 2023 and expected to reach USD 39.15 billion in 2024, at a CAGR 4.12% to reach USD 49.94 billion by 2030.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Antibacterial Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antibacterial Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Antibacterial Drugs Market, highlighting leading vendors and their innovative profiles. These include Allecra Therapeutics GmbH, Allergan PLC, AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Debiopharm Group, Eli Lilly and Company, Entasis Therapeutics by Innoviva, Inc., GlaxoSmithKline PLC, Iterum Therapeutics PLC, Johnson & Johnson Services Inc., Kyorin Pharmaceutical Co., Ltd., Melinta Therapeutics LLC, Merck & Co., Inc., Sanofi-Aventis Groupe S.A., and Teva Pharmaceutical Industries Ltd..
Market Segmentation & Coverage
This research report categorizes the Antibacterial Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:
Routes of Administration
Enteral
Aminoglycoside
Drug Stores & Retail Pharmacies
Americas
Argentina
California
Australia
Denmark
The report offers valuable insights on the following aspects:
- Market Penetration: It presents comprehensive information on the market provided by key players.
- Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
- Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
- Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
- Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
- What is the market size and forecast of the Antibacterial Drugs Market?
- Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antibacterial Drugs Market?
- What are the technology trends and regulatory frameworks in the Antibacterial Drugs Market?
- What is the market share of the leading vendors in the Antibacterial Drugs Market?
- Which modes and strategic moves are suitable for entering the Antibacterial Drugs Market?
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
195 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Antibacterial Drugs Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Growing prevalence of infectious diseases
- 5.1.1.2. Increasing approval and launch of new antibacterial drugs
- 5.1.1.3. Widespread of the generic drugs
- 5.1.2. Restraints
- 5.1.2.1. Patent expiry of the antibacterial drug
- 5.1.3. Opportunities
- 5.1.3.1. Innovation in some novel compounds with improved efficacy, and fewer side effects associated with the drugs
- 5.1.3.2. Adoption of antibacterial drugs in emerging countries
- 5.1.4. Challenges
- 5.1.4.1. Presence of multi-drug resistant bacterial strains
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Antibacterial Drugs Market, by Routes of Administration
- 6.1. Introduction
- 6.2. Enteral
- 6.3. Parenteral
- 7. Antibacterial Drugs Market, by Drug Class
- 7.1. Introduction
- 7.2. Aminoglycoside
- 7.3. B – Lactams
- 7.4. Macrolides
- 7.5. Phenicols
- 7.6. Quinolones
- 7.7. Sulfonamide
- 7.8. Tetracycline
- 8. Antibacterial Drugs Market, by Distribution Channel
- 8.1. Introduction
- 8.2. Drug Stores & Retail Pharmacies
- 8.3. Hospital Pharmacies
- 8.4. Online Pharmacies
- 9. Americas Antibacterial Drugs Market
- 9.1. Introduction
- 9.2. Argentina
- 9.3. Brazil
- 9.4. Canada
- 9.5. Mexico
- 9.6. United States
- 10. Asia-Pacific Antibacterial Drugs Market
- 10.1. Introduction
- 10.2. Australia
- 10.3. China
- 10.4. India
- 10.5. Indonesia
- 10.6. Japan
- 10.7. Malaysia
- 10.8. Philippines
- 10.9. Singapore
- 10.10. South Korea
- 10.11. Taiwan
- 10.12. Thailand
- 10.13. Vietnam
- 11. Europe, Middle East & Africa Antibacterial Drugs Market
- 11.1. Introduction
- 11.2. Denmark
- 11.3. Egypt
- 11.4. Finland
- 11.5. France
- 11.6. Germany
- 11.7. Israel
- 11.8. Italy
- 11.9. Netherlands
- 11.10. Nigeria
- 11.11. Norway
- 11.12. Poland
- 11.13. Qatar
- 11.14. Russia
- 11.15. Saudi Arabia
- 11.16. South Africa
- 11.17. Spain
- 11.18. Sweden
- 11.19. Switzerland
- 11.20. Turkey
- 11.21. United Arab Emirates
- 11.22. United Kingdom
- 12. Competitive Landscape
- 12.1. FPNV Positioning Matrix
- 12.2. Market Share Analysis, By Key Player
- 12.3. Competitive Scenario Analysis, By Key Player
- 13. Competitive Portfolio
- 13.1. Key Company Profiles
- 13.1.1. Allecra Therapeutics GmbH
- 13.1.2. Allergan PLC
- 13.1.3. AstraZeneca PLC
- 13.1.4. Bayer AG
- 13.1.5. Bristol-Myers Squibb Company
- 13.1.6. Debiopharm Group
- 13.1.7. Eli Lilly and Company
- 13.1.8. Entasis Therapeutics by Innoviva, Inc.
- 13.1.9. GlaxoSmithKline PLC
- 13.1.10. Iterum Therapeutics PLC
- 13.1.11. Johnson & Johnson Services Inc.
- 13.1.12. Kyorin Pharmaceutical Co., Ltd.
- 13.1.13. Melinta Therapeutics LLC
- 13.1.14. Merck & Co., Inc.
- 13.1.15. Sanofi-Aventis Groupe S.A.
- 13.1.16. Teva Pharmaceutical Industries Ltd.
- 13.2. Key Product Portfolio
- 14. Appendix
- 14.1. Discussion Guide
- 14.2. License & Pricing
- FIGURE 1. ANTIBACTERIAL DRUGS MARKET RESEARCH PROCESS
- FIGURE 2. ANTIBACTERIAL DRUGS MARKET SIZE, 2023 VS 2030
- FIGURE 3. ANTIBACTERIAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. ANTIBACTERIAL DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. ANTIBACTERIAL DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. ANTIBACTERIAL DRUGS MARKET DYNAMICS
- FIGURE 7. ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2023 VS 2030 (%)
- FIGURE 8. ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
- FIGURE 10. ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
- FIGURE 12. ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 14. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 16. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 18. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 21. ANTIBACTERIAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 22. ANTIBACTERIAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
